報價延遲最少15分鐘:2026/04/15 13:33 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.56 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.04/0.48
|
|
企業價值
1.36B
|
| 資產負債 |
|
每股賬面淨值
3.92
|
| 現金流量 |
|
現金流量率
0.04
|
| 損益表 |
|
收益
376.13M
|
|
每股收益
3.10
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue. |
